ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,565, issued on Feb. 17, was assigned to BrightGene Bio-Medical Technology Co. Ltd. (Jiangsu, China).
"CD44 targeted multi-arm conjugate" was invented by Jiandong Yuan (Jiangsu, China), Yangqing Huang (Jiangsu, China) and Yunsong Song (Jiangsu, China).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a class of multi-branched drug conjugates capable of specifically targeting CD44. The class of compounds specifically binds to CD44, and may target tumor cells and tissues having high expression of CD44, so that the concentration of the conjugate in a target tissue is high, the clinical treatment effect thereof is improved, and toxicity is reduc...